期刊文献+

生物自动反馈式血容量监测模式干预血液透析中低血压对维持性血液透析患者心功能的影响 被引量:1

Effects of biofeedback dialysis mode of blood volume monitoring on cardiac function in the maintenance hemodialysis patients with intra-dialytic hypotension
原文传递
导出
摘要 目的探讨生物自动反馈式血容量监测模式干预血液透析中低血压(IDH)对维持性血液透析(MHD)患者心功能的影响。方法选择2018年9月至2020年12月期间在南京医科大学附属苏州医院行维持性血液透析且多次发生透析低血压的患者40例。分为标准透析(SHD)组和生物自动反馈式血容量监测(BVM)组,每组各20例。第一阶段前12周两组患者均行标准透析,第二阶段后12周分别按照标准透析和生物自动反馈式血容量监测模式进行维持性血液透析治疗。观察两组患者透析低血压的发生率以及透析前后血压、体重、超滤量、B型脑利钠肽(BNP)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室后壁厚度(LVPW)、室间隔舒张期厚度(IVSD)、二尖瓣血流频谱E/A值(E/A)、左室质量指数(LVMI)的变化。结果(1)在第二阶段治疗中BVM组发生需要护理干预的透析低血压次数明显低于SHD组(P<0.05)。(2)BVM组患者在第二阶段治疗时的血压变化差明显小于第一阶段及SHD组(P<0.05)。(3)BVM组患者在第二阶段治疗时,超滤量较第一阶段明显增加,BNP、体重较第一阶段明显下降,差异均有统计学意义(均P<0.05),而SHD组患者在前后两阶段的治疗中体重、BNP及超滤量均无明显变化(均P>0.05)。(4)BVM组患者治疗前后心脏超声指标发生变化,LVEDD、LVPW、IVSD、LVMI较治疗前明显下降,LVEF、E/A较治疗前明显升高,差异均有统计学意义(均P<0.05),而SHD组患者的心脏超声指标治疗前后并无明显变化(均P>0.05)。结论生物自动反馈式血容量监测透析模式明显减少了透析低血压的发生,且此种透析模式可有效改善透析低血压患者的心功能情况。 Objective To discuss the effects of biofeedback dialysis mode of blood volume monitoring on cardiac function in the maintenance hemodialysis(MHD)patients with intra-dialytic hypotension(IDH).Methods 40 patients who underwent maintenance hemodialysis in Suzhou Hospital Affiliated to Nanjing Medical University from September 2018 to December 2020 and had IDH for many times were selected.They were divided into standard dialysis(SHD)group and biofeedback dialysis mode of blood volume monitoring(BVM)group,with 20 cases in each group.In the first 12 weeks of the first stage,the patients in both groups were treated with standard dialysis,and in the second 12 weeks,they were treated with maintenance hemodialysis according to standard dialysis and biofeedback dialysis mode of blood volume monitoring.The incidence of IDH and the changes of blood pressure before and after dialysis,body weight,ultrafiltration volume,B-type brain natriuretic peptide(BNP),left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular posterior wall thickness(LVPW),inlet ventricular septal defect(IVSD),mitral valve flow spectrum E/A value(E/A)and left ventricular mass index(LVMI)were observed.Results(1)In the second stage of treatment,the number of IDH requiring nursing intervention in BVM group was significantly lower than that in SHD group(P<0.05).(2)The difference of blood pressure change in BVM group during the second stage of treatment was significantly lower than that in the first stage and SHD group(P<0.05).(3)In the second stage of treatment,the ultrafiltration volume of patients in BVM group was significantly higher than that in the first stage,and the BNP and body weight were significantly lower than that in the first stage(all P<0.05).However,the body weight,BNP and ultrafiltration volume of patients in SHD group had no significan change in the two stages of treatment(all P>0.05).(4)After treatment,the LVID,LVPW,IVSD and LVMI in BVM group were significantly lower than those before treatment,and LVEF and E/A were significantly higher than those before treatment(all P<0.05).However,there was no significant change in echocardiographic indexes in SHD group before and after treatment(all P>0.05).Conclusions The biofeedback dialysis mode of blood volume monitoring can significantly reduce the occurrence of IDH,and this dialysis mode can effectively improve the cardiac function of MHD patients with hypotension.
作者 华青 陈强 王红梅 王悦至 Hua Qing;Chen Qiang;Wang Hongmei;Wang Yuezhi(Department of Nephrology,Gusu School,Nanjing Medical University,Suzhou Municipal Hospital,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215008,China)
出处 《中国医师杂志》 CAS 2022年第4期551-555,共5页 Journal of Chinese Physician
基金 苏州市重点学科(肾脏病学)(Szxk201807)。
关键词 血液透析 低血压 血容量监测 超声心动描记术 Hemodialysis Hypotension Blood volume monitoring Echocardiography
  • 相关文献

参考文献13

二级参考文献79

  • 1余金波,邹建洲,刘中华,沈波,徐少伟,滕杰,丁小强.维持性血液透析患者透析中低血压的危险因素研究[J].中国血液净化,2012,11(4):189-193. 被引量:63
  • 2陈丁,孙岩,孙波,闫国强.血液透析低血压发生的易感因素及防治措施[J].中国血液净化,2012,11(6):336-339. 被引量:25
  • 3陈恩静,甘华,谯林.血液透析对慢性肾衰竭患者血浆氧化型低密度脂蛋白水平的影响[J].临床内科杂志,2005,22(6):400-402. 被引量:2
  • 4刘玉辉,张战斌.制备喜勃酮用的中间体及其制备方法:中国,1176081[P].2004-11-17.(CA2005,142:411367).
  • 5U.S.Renal Data System,USRDS 2007 Annual Data Report:Atlas of End-Stage Renal Disease in the United States,National Institutes of Health,National Institute of Diabetes and Digestive and Kidney Diseases[R].Bethesda,2007.
  • 6Lee SC,Stevens TL,Sandberg SM,et al.The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the out-patient treatment of heart failure[J].J Card Fail,2002,8 (3):149-154.
  • 7Wang TJ,Larson MG,Levy D,et al.Plasma natriuretic peptide levels and the risk of cardiovascular events and death[J].NEJM,2004,350:655-663.
  • 8Tsutamoto T,Wado A,Maedo K,et al.Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symp tomatic left ventricular dysfunction[J].Circulation,1997,96:509-516.
  • 9Goetze JP,Christoffersen C,Perko M,et al.Increase cardiac BNP expression associated with myocardial ischemia[J].FASEB J,2003,17 (9):1105-1107.
  • 10Kawai K,Hata K,Takaoka H,et al.Plasma brain natriuretic peptide as a novel therapeutic indicatror in idiopathic dilated cardiomyopathy during beta-blocker therapy:a potential of hormone-gnrided treatment[J].Am Heart J,2001,141(6):925-932.

共引文献193

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部